You have 9 free searches left this month | to do more

apr-246

Apr 246 is a drug used to treat Chronic Myelomonocytic Leukemia, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, and other conditions. Apr 246 is being actively studied in 3 studies and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
Aprea TherapeuticsDana Farber Cancer Institute
Groupe Francophone des MyelodysplasiesCambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
H. Lee Moffitt Cancer Center and Research InstituteEdinburgh Cancer Research Centre, The University of Edinburgh
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Active, not recruiting
  • Myeloid Malignancy
  • APR-246
  • +2 more
  • New Haven, Connecticut
  • +7 more
2021-07-28
Jul 28, 2021
P
Terminated
  • Oesophageal Carcinoma
  • APR-246
  • Clayton, Victoria, Australia
  • +4 more
2021-12-10
Dec 10, 2021
A
Active, not recruiting
  • Acute Myeloid Leukemia or Myelodysplastic Syndromes
  • APR-246
  • Tampa, Florida
  • +6 more
2021-09-17
Sep 17, 2021
H
Active, not recruiting
  • Myelodysplastic Syndrome
  • +3 more
  • Tampa, Florida
  • +5 more
2022-01-03
Jan 3, 2022
G
Unknown status
  • Myelodysplastic Syndrome With Gene Mutation
  • +3 more
  • Lille, France
  • +6 more
2020-01-29
Jan 29, 2020
A
Completed
  • Hematologic Neoplasms
  • Prostatic Neoplasms
  • APR-246
  • Göteborg, Sweden
  • +5 more
2019-07-29
Jul 29, 2019
A
Completed
  • High-grade Serous Ovarian Cancer
  • APR-246
  • Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
  • Gent, Belgium
  • +11 more
2019-10-09
Oct 9, 2019
A
Completed
  • Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
  • APR-246
  • Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
  • Los Angeles, California
  • +54 more
2019-07-29
Jul 29, 2019